Order Article Reprints

Kao C-C, Ho C-L, Yang M-H, Tsai Y-T, Liu S-Y, Chang P-Y, Wu Y-Y, Chen J-H, Huang T-C, Yehn R-H, et al. Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. Journal of Clinical Medicine. 2022; 11(8):2183. https://doi.org/10.3390/jcm11082183

Kao, Chien-Chang, Ching-Liang Ho, Ming-Hsin Yang, Yi-Ta Tsai, Shu-Yu Liu, Ping-Ying Chang, Yi-Ying Wu, Jia-Hong Chen, Tzu-Chuan Huang, Ren-Hua Yehn, and et al. 2022. "Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors" Journal of Clinical Medicine 11, no. 8: 2183. https://doi.org/10.3390/jcm11082183

Kao, C.-C., Ho, C.-L., Yang, M.-H., Tsai, Y.-T., Liu, S.-Y., Chang, P.-Y., Wu, Y.-Y., Chen, J.-H., Huang, T.-C., Yehn, R.-H., Dai, M.-S., Chen, Y.-C., Sun, G.-H., & Cha, T.-L. (2022). Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors. Journal of Clinical Medicine, 11(8), 2183. https://doi.org/10.3390/jcm11082183